PT  - JOURNAL ARTICLE
AU  - Harrington, Patrick
AU  - Doores, Katie J.
AU  - Radia, Deepti
AU  - O’Reilly, Amy
AU  - Jeff Lam, Ho Pui
AU  - Seow, Jeffrey
AU  - Graham, Carl
AU  - Lechmere, Thomas
AU  - McLornan, Donal
AU  - Dillon, Richard
AU  - Shanmugharaj, Yogita
AU  - Espehana, Andreas
AU  - Woodley, Claire
AU  - Saunders, Jamie
AU  - Curto-Garcia, Natalia
AU  - O’Sullivan, Jennifer
AU  - Kordasti, Shahram
AU  - Malim, Michael H.
AU  - Harrison, Claire
AU  - de Lavallade, Hugues
TI  - Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML
AID  - 10.1101/2021.04.15.21255482
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.15.21255482
4099  - http://medrxiv.org/content/early/2021/04/22/2021.04.15.21255482.short
4100  - http://medrxiv.org/content/early/2021/04/22/2021.04.15.21255482.full
AB  - Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including patients with Chronic Myeloid Leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised.We evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 CML patients. Seroconversion and cellular immune response prior and after vaccination were assessed.By day 21 post-vaccination, anti-Spike IgG were detected in 14/16 (87.5%) of CML patients and all developed a neutralizing antibody response (ID50>50), including medium (ID50 of 200-500) or high (501-2000) neutralising antibodies titres in 9/16 (56.25%) patients. T cell response was seen in 14/15 (93.3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response 9/15, polyfunctional CD8+ T cell response 9/15).These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most CML patients with both neutralizing antibodies and polyfunctional T-cell responses seen, in contrast to patients with solid tumour or lymphoid haematological malignancies.Funding King’s Together Rapid COVID-19 Call awards to MHM, KJD; A Huo Family Foundation Award to MHM, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM; Wellcome Trust Investigator Award 106223/Z/14/Z to MHM; CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to KJDCompeting Interest StatementThe authors have declared no competing interest.Funding StatementKings Together Rapid COVID19 Call awards to MHM, KJD, A Huo Family Foundation Award to MHM, KJD, Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM, Wellcome Trust Investigator Award 106223/Z/14/Z to MHM, CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1), Fondation Dormeur, Vaduz for funding equipment to KJDAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol (Integrated Research Application System identification number: 285396; Research and Ethics Committe identification number: 20/WM/0187) was reviewed by the West Midlands - Edgbaston Research and Ethics Committee, NHS Health Research Authority, U.K. and the Health Research Authority, Health and Care Research Wales. A favourable opinion was confirmed on 22/6/2020 confirming ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials